Bristol Myers Squibb to present 80+ studies across 20+ cancers at ASCO 2025
Bristol Myers Squibb announced the presentation of data across its oncology portfolio and pipeline at the 2025 American Society of Clinical Oncology (ASCO®) Annual Meeting to be held May 30-June 3 in Chicago, Illinois. Data from more than 80 company-sponsored studies, investigator-sponsored studies, and collaborations showcase results spanning more than 20 cancer types.
“Bristol Myers Squibb is advancing novel approaches to address high unmet needs in cancer and at this year’s ASCO meeting, we are highlighting data across a range of assets, including our targeted therapy pipeline, and new data that support the use of our portfolio in earlier lines of treatment, enhancing or improving patient outcomes,” said Samit Hirawat, M.D., executive vice president, chief medical officer, head of development, Bristol Myers Squibb. “We are a company that has redefined the cancer care landscape and we are leveraging our deep expertise, combined with innovative technologies and modalities, to deliver new medicines and breakthrough advances for patients.”
Key data to be presented by Bristol Myers Squibb and its collaborators at ASCO include:
Highlighting our leading portfolio with long-term survival data and intervention earlier in the treatment of disease
- Results from the independent Phase 3 randomized NIVOPOSTOP (GORTEC 2018-01) study evaluating adjuvant nivolumab added to radio-chemotherapy in patients with resected head and neck squamous cell carcinoma (HNSCC) at high risk of relapse will be presented during the plenary session of the meeting
- Late-breaking 5-year analysis of overall survival (OS), a key secondary endpoint, in the Phase 3 CheckMate -816 study of Opdivo® (nivolumab) in combination with chemotherapy as a neoadjuvant treatment for resectable (tumors ≥4 cm or node positive) non-small cell lung cancer (NSCLC) compared to chemotherapy alone
- Late-breaking data highlighting updated survival results and an exploratory biomarker analysis from the Phase III CheckMate -77T study evaluating the perioperative treatment with neoadjuvant Opdivo in combination with chemotherapy followed by surgery and adjuvant single-agent Opdivo for certain patients with resectable NSCLC
- 5-year OS results from the Phase III CheckMate -577 study evaluating adjuvant Opdivo in adult patients with completely resected esophageal or gastroesophageal junction cancer who have residual disease following neoadjuvant chemoradiotherapy (CRT)
- First disclosure of OS results and updated duration of response (DoR) data from the Phase III COMMANDS study evaluating the benefit of Reblozyl®(luspatercept-aamt) vs. epoetin alfa (EA) for transfusion independence (TI) in erythropoiesis stimulating agent (ESA)-naive patients with very low-, low-, or intermediate-risk myelodysplastic syndromes (MDS)
Advancing our oncology pipeline
- Updated safety and efficacy results from the first-in-human Phase 1/II CA240-0007 study evaluating BMS-986504, a potential first-in-class MTA-cooperative PRMT5 inhibitor, in heavily pretreated patients with advanced, unresectable or metastatic solid tumors with homozygousMTAP deletions
- OS, progression free survival (PFS) and overall response rate (ORR) data from the PhaseII KRYSTAL-7 study evaluating first-lineKRAZATI®(adagrasib) plus pembrolizumab for the treatment of advanced/metastaticKRASG12C-mutated NSCLC, regardless of PD-L1 status
- Results from two Phase 1 studies of EGFR x HER3 bispecific antibody-drug conjugate, iza-bren (BL-B01D1), in patients with locally advanced or metastatic small cell lung cancer (SCLC) and in patients with locally advanced or metastatic NSCLC with driver genomic alterations (GA) outside of classic EGFR mutations
Furthering the science of cell therapy
- Analysis of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) timing in over 1,500 patients treated with Breyanzi® (lisocabtagene maraleucel; liso-cel) in clinical trials and real-world experience across indications of B-cell non-Hodgkin lymphoma providing a more precise window into the onset and duration of CRS/ICANS for patient management after CAR T cell treatment
- Assessment of normal plasma cell biomarkers after arlocabtagene autoleucel (arlo-cel) treatment in patients with ≥3L relapsed or refractory multiple myeloma suggesting preservation of the humoral immune system when targeting the GPRC5D antigen
View select Bristol Myers Squibb studies at the 2025 ASCO Annual Meeting HERE.
